Diabetes

Feb. 22 (Bloomberg) — Bloomberg’s Peter Cook reports on glaxosmithkline Plc’s Avandia diabetes-treatment drug. Shares of the drugmaker fell after US Senators released a report showing that safety reviewers had urged the US Food and Drug Administration to take Avandia off the market because it caused an increased risk of heart attacks. (Source: Bloomberg)

Gestational Diabetes Underdiagnosed